Korean J Obstet Gynecol.  2012 Oct;55(10):761-765.

Superior vena cava syndrome secondary to hickman catheter in the advanced cervical cancer patient treated with concurrent chemoradiotherapy: A case report

• Kang PN
• Choi CH
• Lee JW
• Kim BG
• Bae DS

Abstract

Most of superior vena cava syndrome are caused by malignant tumors involving the mediastinum (usually lung cancer or lymphoma). However, iatrogenic cause has become more important since it has become common to utilize long-term central venous catheters for chemotherapy or hyperalimentation therapy. Although the cancer patients are also at relatively high risk, there are only few case reports of superior vena cava syndrome in gynecologic cancer. We present a case of iatrogenic superior vena cava syndrome related with Hickman catheter in advanced cervical cancer patient treated with concurrent chemoradiotherapy.

Keyword

Superior vena cava syndrome; Central venous catheter; Hickman catheter; Chemoradiotherapy; Cervical neoplasm

MeSH Terms

Catheters
Central Venous Catheters
Chemoradiotherapy
Humans
Lung Neoplasms
Mediastinum
Superior Vena Cava Syndrome
Uterine Cervical Neoplasms
Vena Cava, Superior

Figure

• 

  Fig. 1 Normal chest X-ray findings.

• 

  Fig. 2 Chest computed tomography revealed thrombosis in superior vena cava, right subclavian vein, left brachiocephalic vein and azygous vein without evidence of cancer metastasis.

Reference

1. Griffin D, Martino MA, Hoffman MS. Superior vena cava syndrome during chemotherapy for stage 3c fallopian tube adenocarcinoma. Gynecol Oncol. 2004. 93:257–259.

2. Matthews JA, Blake HA, Hall DJ. Iatrogenic superior vena cava syndrome treated with streptokinase. Gynecol Oncol. 1987. 26:119–122.

3. Puleo JG, Clarke-Pearson DL, Smith EB, Barnard DE, Creasman WT. Superior vena cava syndrome associated with gynecologic malignancy. Gynecol Oncol. 1986. 23:59–64.

4. Kitagawa R, Katsumata N, Ando M, Shimizu C, Fujiwara Y, Yoshikawa H, et al. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. Gynecologic Oncology. 2012. 125:307–311.

5. Choi IJ, Cha MS, Park ES, Han MS, Choi Y, Je GH, et al. The efficacy of concurrent cisplatin and 5-flurouracil chemotherapy and radiation therapy for locally advanced cancer of the uterine cervix. J Gynecol Oncol. 2008. 19:129–134.

6. Schifferdecker B, Shaw JA, Piemonte TC, Eisenhauer AC. Nonmalignant superior vena cava syndrome: pathophysiology and management. Catheter Cardiovasc Interv. 2005. 65:416–423.

7. Bertrand M, Presant CA, Klein L, Scott E. Iatrogenic superior vena cava syndrome. A new entity. Cancer. 1984. 54:376–378.

8. Estes JM, Rocconi R, Straughn JM, Bhoola S, Leath CA, Alvarez RD, et al. Complications of indwelling venous access devices in patients with gynecologic malignancies. Gynecol Oncol. 2003. 91:591–595.

9. Markman M. Diagnosis and management of superior vena cava syndrome. Cleve Clin J Med. 1999. 66:59–61.

10. Preston CI, Poynton CH, Williams LB. Intermittent superior vena cava syndrome caused by a Hickman catheter. Clin Oncol (R Coll Radiol). 1992. 4:60–61.

11. Roberts JR, Bueno R, Sugarbaker DJ. Multimodality treatment of malignant superior vena caval syndrome. Chest. 1999. 116:835–837.

12. Akl EA, Vasireddi SR, Gunukula S, Yosuico VE, Barba M, Sperati F, et al. Anticoagulation for patients with cancer and central venous catheters. Cochrane Database Syst Rev. 2011. (2):CD006468.

13. Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW, et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet. 2009. 373:567–574.

14. Prandoni P. Prophylaxis of catheter-related thrombosis in cancer patients. Lancet. 2009. 373:523–524.

15. Minassian VA, Sood AK, Lowe P, Sorosky JI, Al-Jurf AS, Buller RE. Longterm central venous access in gynecologic cancer patients. J Am Coll Surg. 2000. 191:403–409.